Antimicrobial resistance (AMR) is no longer a distant threat — it’s here, and it’s growing.
Across hospitals worldwide, once-treatable infections are defying conventional therapies, driven by multidrug-resistant organisms (MDROs) and healthcare-associated infections (HAIs). What used to be routine medical procedures can now carry life-threatening risks, with patients facing extended hospital stays, severe complications, or even sepsis.
By 2050, AMR is projected to cause 10 million deaths annually and cost the global economy up to $100 trillion. The stakes are high — but innovation, diagnostics, and stronger clinical strategies can help us turn the tide.